Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On November 17, 2022, InVivo Therapeutics Holdings Corp. (the "Company") entered
into an amendment to the existing employment agreement dated December 24, 2018
(the "Employment Agreement") with Richard Christopher, the Company's Chief
Financial Officer (the "Amendment"). The Amendment provides for an increase from
six (6) to twelve (12) months of continuation of Mr. Christopher's health
insurance benefits under the Company's employee group health insurance plan from
the date of termination in the event Mr. Christopher's employment is terminated
by the Company without Cause or if he terminates his employment for Good Reason
(each as defined in the Employment Agreement), in each case prior to, or more
than 12 months following, a Change in Control (as defined in the Employment
Agreement), unless Mr. Christopher becomes eligible for coverage under a new
employer group's health plan.
The foregoing description of the Amendment is qualified in its entirety by
reference to the full text of the Amendment, a copy of which is filed herewith
as Exhibit 10.1, and is incorporated by reference herein. Unless otherwise
specified, capitalized terms used above without definition have the meanings set
forth in the Employment Agreement or the Amendment.
2
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit
Number Description
10.1 Amendment to Employment Agreement, by and between InVivo
Therapeutics Holdings Corp. and Richard Christopher, dated
November 17, 2022.
104 Cover Page Interactive Data File - the cover page iXBRL tags are
embedded within the inline XBRL document.
3
© Edgar Online, source Glimpses